Abstract: GPC3 T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GPC3, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

Abstract: Claudin 18.2 T cell antigen couplers (TACs) polypeptides having (i) an antigen-binding domain that binds Claudin 18.2, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

Abstract: GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.

Abstract: Claudin 18.2 T cell antigen couplers (TACs) polypeptides having (i) an antigen-binding domain that binds Claudin 18.2, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided. Nucleic acids encoding the claudin 18/2 TACs are also provided.

Abstract: Claudin 18.2 T cell antigen couplers (TACs) polypeptides having (i) an antigen-binding domain that binds Claudin 18.2, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided. Nucleic acids encoding the claudin 18/2 TACs are also provided.

Abstract: A modular control unit (100) is adaptable, in terms of interface functions, for an electric motor selected from a predetermined number i of electric motors, in particular electric motors of the same power class. The control unit (100) has at least two printed circuit boards (L1, L2), selected from a set of N different printed circuit boards (L1, L2, . . . , LN). Interface functions, electrical components, electronic components or control units for the operation of the electric motor are located on the printed circuit boards.

Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a synthetic oligonucleotide.

Abstract: A method of treating a subject having liver cancer can include administering a synthetic oligonucleotide to a subject having liver cancer, the oligonucleotide comprising a sequence that is at least 80% identical to at least one of SEQ ID NO:1-12 (e.g., a miR-34 or miR-215 mimic); and administering sorafenib to the subject, wherein the molar ratio of sorafenib:oligonucleotide administered to the subject is in the range of about 10-2000 (e.g., a ratio that provides a superior, for example synergistic or greater than additive, effect).

Abstract: Methods of inhibiting, and preventing the proliferation of, cancer cells, as well as treating cancer in an individual (e.g., a liver cancer, for example hepatocellular carcinoma) can include providing both a synthetic miR-34 family molecule and a c-Met inhibitor (e.g., tivantinib) to an individual in need thereof. The combination of the synthetic miRNA molecule and c-Met inhibitor can provide a desirable or superior effect, for example a more efficacious treatment than an alternative therapy, or the synthetic miRNA molecule or c-Met inhibitor alone. In some embodiments, the combinations provide a synergistic or greater than additive effect, or reduce toxicity and/or other side effects.

Abstract: A database language is extended to define constraints on a data model (e.g., entity-relationship model) rather than the concrete database. The constraints can be declarative (e.g., constraints that are defined using expressions of the database language) or programmatic (e.g., constraints that are defined as a stored procedure implemented in a domain specific language). By storing the constraints at a higher level than the database level, the constraints can be performed without changing the persistency of the database. Also disclosed are techniques for handling of constraints on partially loaded entities.

Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a microRNA.

Abstract: A method of treating a subject having liver cancer can include administering a synthetic oligonucleotide to a subject having liver cancer, the oligonucleotide comprising a sequence that is at least 80% identical to at least one of SEQ ID NO:1-12 (e.g., a miR-34 or miR-215 mimic); and administering sorafenib to the subject, wherein the molar ratio of sorafenib:oligonucleotide administered to the subject is in the range of about 10-2000 (e.g., a ratio that provides a superior, for example synergistic or greater than additive, effect).

Abstract: A database language is extended to define constraints on a data model (e.g., entity-relationship model) rather than the concrete database. The constraints can be declarative (e.g., constraints that are defined using expressions of the database language) or programmatic (e.g., constraints that are defined as a stored procedure implemented in a domain specific language). By storing the constraints at a higher level than the database level, the constraints can be performed without changing the persistency of the database. Also disclosed are techniques for handling of constraints on partially loaded entities.

Abstract: This invention is based in part on the discovery that miR-34 is independent of p53. It has been discovered that miR-34 functions in a TP53-independent tumor suppression pathway. Specifically, miR-34-induced inhibition of cancer cell growth was found to be the same in p53-normal and p53-deficient cells. Thus, miR-34 has a more central role during tumor suppression that is uncoupled from p53. In the absence of p53, miR-34, unlike certain other miRNAs, is sufficient to induce an up-regulation of genes known to be regulated by p53, including but not limited to p21CIP1/WAF1 (CDKN1A), PUMA, BAX, NOXA, PHLDA3, and MDM2 and a down-regulation of HDAC1. Therefore, these biomarkers can be used as biomarkers of miR-34 activity. The invention is further based on the discovery that some of these biomarkers are indispensable for a therapeutic response to miR-34 activity, and are thus prerequisite biomarkers of miR-34 activity.

Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a synthetic oligonucleotide.

Abstract: The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a microRNA.

Abstract: Embodiments of the present invention include in-memory processing for data warehouse applications. In one embodiment, data records from a data warehouse application are stored in a data storage structure of an in-memory database. Data received from the data warehouse may be stored in a queue and loaded into the data storage structure according to predefined rules. Stored data records are associated with in-memory database transactions that caused the stored data record to be stored, and may further be associated with transactions that caused the stored data records to be changed. A mapping is generated to associate requests from the data warehouse application with in-memory database transactions. The data warehouse application may retrieve data in a change data format calculated on-the-fly.

Abstract: Embodiments of the present invention include in-memory processing for data warehouse applications. In one embodiment, data records from a data warehouse application are stored in a data storage structure of an in-memory database. Data received from the data warehouse may be stored in a queue and loaded into the data storage structure according to predefined rules. Stored data records are associated with in-memory database transactions that caused the stored data record to be stored, and may further be associated with transactions that caused the stored data records to be changed. A mapping is generated to associate requests from the data warehouse application with in-memory database transactions. The data warehouse application may retrieve data in a change data format calculated on-the-fly.

Abstract: A method and device are provided for limiting, in a first operating condition, a motor vehicle internal-combustion engine torque. The operating condition, resulting from an operation of a motor vehicle brake, when the engine torque is simultaneously demanded by a driver's intention indicator, differs from a second operating condition, in which the brake is not operated. The limiting takes place at least partially by way of a controlled reduction of an advance angle efficiency in the first operating condition in comparison to the second operating condition.

Abstract: A method for limiting the rotational speed in an internal combustion engine is provided. A detection device detects prevailing operating parameters. Based on the prevailing operating parameters, the control variables for the ignition, injection and throttle valve position are determined. When the prevailing rotational speed (nact) reaches a preselectable maximum rotational speed value (nmax), through a change in at least one of the control variables, the rotational speed is limited to this preselectable maximum rotational speed value, and a hard rotational speed limitation is achieved by fade-in and fade-out of the injection and/or by intervention in the ignition with simultaneous support by the throttle valve and whereby a soft rotational speed limitation is achieved by retarding the ignition and by varying the throttle valve. Activation of a soft rotational speed limitation or hard rotational speed limitation is coordinated by the control unit according to the requirements of driving performance.